Appropriate use of cervical cancer vaccine

Gregory Zimet, Marcia Shew, Jessica A. Kahn

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Human papillomavirus (HPV) is a necessary, though not sufficient, cause of cervical cancer. Two vaccines have been developed that prevent two HPV types associated with 70% of cervical cancers. One of the vaccines (a quadrivalent vaccine) also prevents two HPV types associated with 90% of genital warts. Both HPV vaccines have shown very good efficacy and safety. This review summarizes the guidelines for use of the quadrivalent vaccine published by the Advisory Committee on Immunization Practices, presents data on vaccine efficacy and safety, and gives an overview of the findings of cost-effectiveness studies. In addition, we summarize the research on the attitudes of parents and health care providers toward HPV vaccine and critically evaluate controversial and challenging issues surrounding HPV vaccination, including concerns about sexual disinhibition and potential obstacles to vaccine distribution and uptake.

Original languageEnglish
Pages (from-to)223-236
Number of pages14
JournalAnnual Review of Medicine
Volume59
DOIs
StatePublished - 2008

Fingerprint

Cancer Vaccines
Uterine Cervical Neoplasms
Vaccines
Papillomavirus Vaccines
Immunization
Safety
Condylomata Acuminata
Advisory Committees
Cost effectiveness
Health care
Health Personnel
Cost-Benefit Analysis
Vaccination
Parents
Guidelines
Research

Keywords

  • Adolescent
  • HPV
  • Human papillomavirus
  • Immunization
  • Vaccination

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Cite this

Appropriate use of cervical cancer vaccine. / Zimet, Gregory; Shew, Marcia; Kahn, Jessica A.

In: Annual Review of Medicine, Vol. 59, 2008, p. 223-236.

Research output: Contribution to journalArticle

@article{c347e91a865c4d899af9fa36c0fb4627,
title = "Appropriate use of cervical cancer vaccine",
abstract = "Human papillomavirus (HPV) is a necessary, though not sufficient, cause of cervical cancer. Two vaccines have been developed that prevent two HPV types associated with 70{\%} of cervical cancers. One of the vaccines (a quadrivalent vaccine) also prevents two HPV types associated with 90{\%} of genital warts. Both HPV vaccines have shown very good efficacy and safety. This review summarizes the guidelines for use of the quadrivalent vaccine published by the Advisory Committee on Immunization Practices, presents data on vaccine efficacy and safety, and gives an overview of the findings of cost-effectiveness studies. In addition, we summarize the research on the attitudes of parents and health care providers toward HPV vaccine and critically evaluate controversial and challenging issues surrounding HPV vaccination, including concerns about sexual disinhibition and potential obstacles to vaccine distribution and uptake.",
keywords = "Adolescent, HPV, Human papillomavirus, Immunization, Vaccination",
author = "Gregory Zimet and Marcia Shew and Kahn, {Jessica A.}",
year = "2008",
doi = "10.1146/annurev.med.59.092806.131644",
language = "English",
volume = "59",
pages = "223--236",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Appropriate use of cervical cancer vaccine

AU - Zimet, Gregory

AU - Shew, Marcia

AU - Kahn, Jessica A.

PY - 2008

Y1 - 2008

N2 - Human papillomavirus (HPV) is a necessary, though not sufficient, cause of cervical cancer. Two vaccines have been developed that prevent two HPV types associated with 70% of cervical cancers. One of the vaccines (a quadrivalent vaccine) also prevents two HPV types associated with 90% of genital warts. Both HPV vaccines have shown very good efficacy and safety. This review summarizes the guidelines for use of the quadrivalent vaccine published by the Advisory Committee on Immunization Practices, presents data on vaccine efficacy and safety, and gives an overview of the findings of cost-effectiveness studies. In addition, we summarize the research on the attitudes of parents and health care providers toward HPV vaccine and critically evaluate controversial and challenging issues surrounding HPV vaccination, including concerns about sexual disinhibition and potential obstacles to vaccine distribution and uptake.

AB - Human papillomavirus (HPV) is a necessary, though not sufficient, cause of cervical cancer. Two vaccines have been developed that prevent two HPV types associated with 70% of cervical cancers. One of the vaccines (a quadrivalent vaccine) also prevents two HPV types associated with 90% of genital warts. Both HPV vaccines have shown very good efficacy and safety. This review summarizes the guidelines for use of the quadrivalent vaccine published by the Advisory Committee on Immunization Practices, presents data on vaccine efficacy and safety, and gives an overview of the findings of cost-effectiveness studies. In addition, we summarize the research on the attitudes of parents and health care providers toward HPV vaccine and critically evaluate controversial and challenging issues surrounding HPV vaccination, including concerns about sexual disinhibition and potential obstacles to vaccine distribution and uptake.

KW - Adolescent

KW - HPV

KW - Human papillomavirus

KW - Immunization

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=39649100449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39649100449&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.59.092806.131644

DO - 10.1146/annurev.med.59.092806.131644

M3 - Article

VL - 59

SP - 223

EP - 236

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -